Plasminogen and tissue-type plasminogen activator deficiency as risk factors for thromboembolic disease.
OBJECTIVE
To review the published evidence for an association between a deficiency of plasminogen or tissue-type plasminogen activator (tPA) and the risk of thrombosis.


METHODS
Review of the medical literature, with an emphasis on the last 10 years.


METHODS
After an initial assessment of the literature, including review of clinical study design and laboratory methods, a draft manuscript summarizing the findings was prepared and circulated to participants in the College of American Pathologists Conference on Diagnostic Issues in Thrombophilia. The key findings and each recommendation were presented for discussion at the conference. Recommendations were accepted if a consensus of the 27 experts attending the conference was reached. The results of the discussion were used to revise the manuscript into its final form.


CONCLUSIONS
The consensus of the conference was that routine laboratory assessment of plasminogen and tPA concentration in patients with thrombophilia is not warranted at this time. Analysis of plasminogen and tPA gene alterations in patients with thrombophilia is also not warranted at this time. Determination of plasminogen concentration should be performed in patients suspected of having ligneous conjunctivitis.
Brandt
John T
JT
Eli Lilly & Co, Lilly Corporate Center, Indianapolis, Ind 46285, USA.
D001780:Blood Coagulation Tests; D005342:Fibrinolysis / Q000502:physiology; D006801:Humans; D010958:Plasminogen / Q000032:analysis / Q000172:deficiency* / Q000378:metabolism; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D013923:Thromboembolism / Q000097:blood / Q000175:diagnosis* / Q000209:etiology; D019851:Thrombophilia / Q000097:blood / Q000150:complications / Q000175:diagnosis; D010959:Tissue Plasminogen Activator / Q000097:blood / Q000172:deficiency*
D010958:Plasminogen; D010959:Tissue Plasminogen Activator